Difference between revisions of "Altretamine (Hexalen)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 17: Line 17:
  
 
==Also known as==
 
==Also known as==
Hexamethylmelamine or HMM.
+
*'''Generic names:''' Hexamethylmelamine, HMM
 +
*'''Brand name:''' Altretamine
  
 
==References==
 
==References==
Line 23: Line 24:
  
 
[[Category:Drug index]]
 
[[Category:Drug index]]
[[Category:Chemotherapy]]
 
 
[[Category:Oral medications]]
 
[[Category:Oral medications]]
 +
 
[[Category:Alkylating agents]]
 
[[Category:Alkylating agents]]
 
[[Category:Ovarian cancer medications]]
 
[[Category:Ovarian cancer medications]]
  
 
[[Category:Drugs FDA approved in 1990]]
 
[[Category:Drugs FDA approved in 1990]]

Revision as of 18:26, 29 October 2017

General information

Class/mechanism: Alkylating-like, exact mechanism unknown—can form covalent adducts with tissue macromolecules including DNA.[1][2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 12/26/1990: Initial FDA approval

Also known as

  • Generic names: Hexamethylmelamine, HMM
  • Brand name: Altretamine

References